Press releasePRNewswire
Indivior Pharmaceuticals
INDV · NASDAQ
$34.77+$0.90 (+2.66%)TodayMarket closed ·
Prev close $33.87
Latest news
- Press releasePRNewswire
ACT NOW - The M&A Class Action Firm Is Investigating the Merger -- FHB, INDV, ITGR, and LNTH
- Press releaseBusiness Wire
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
- Press releaseGlobe Newswire
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
- Press releaseBusiness Wire
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
- News
Indivior Q2 2026 Earnings Call: Complete Transcript
- Press releaseBusiness Wire
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
- Press releasePRNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV)
- NewsVandana Singh
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
- Press releaseBusiness Wire
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
- News
Supernus Pharmaceuticals To Merge With Indivior Pharmaceuticals; SUPN Stockholders Will Receive 1.5401 Shares Of INDV Per SUPN Share; Indivior Stockholders Will Receive One-Time Special Cash Dividend Of $1B Immediately Prior To Closing; Expected To Generate $125M In Annual Cost Synergies
- Press releaseGlobe Newswire
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
- Press releaseGlobe Newswire
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
- News
Earnings Scheduled For April 30, 2026
- News
Indivior Q1 Adj. EPS $0.96 Beats $0.66 Estimate, Sales $317.000M Beat $272.840M Estimate
- Press releaseGlobe Newswire
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
- News
Insights into Indivior Pharmaceuticals Q4 Earnings
- News
Indivior Q4 Adj. EPS $0.82 Beats $0.67 Estimate, Sales $358.000M Beat $305.620M Estimate
- Press releaseGlobe Newswire
Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results
- Press releaseGlobe Newswire
Indivior Provides Full-Year 2026 Financial Guidance and Business Update
- Press releasePRNewswire
Indivior Announces Inclusion in the S&P SmallCap 600® Index
- Press releasePRNewswire
New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations
- Press releasePRNewswire
CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
- NewsAvi Kapoor
Elastic, Veeva Systems, HIVE Digital And Other Big Stocks Moving Lower In Friday's Pre-Market Session
- Press releasePRNewswire
Indivior Concludes Legacy U.S. Department of Justice Matter
- Press releasePRNewswire
Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference
- Press releasePRNewswire
Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine
- Press releasePRNewswire
Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance
- Press releasePRNewswire
Indivior to Participate in the Stifel 2025 Healthcare Conference
- Press releasePRNewswire
Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th
- Press releasePRNewswire
Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment
- Press releasePRNewswire
Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation
- Press releasePRNewswire
Indivior to Participate in Upcoming Investor Events
- Press releasePRNewswire
Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance
- Press releasePRNewswire
Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
- Press releasePRNewswire
Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder
- Press releasePRNewswire
Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st
- Press releasePRNewswire
Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs
- News
Indivior To Delist From LSE, Citing US Revenue Dominance And Higher Nasdaq Liquidity In Move To Streamline Operations
- NewsVandana Singh
European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat
- NewsAvi Kapoor
Tesla, A. O. Smith And Other Big Stocks Moving Lower In Friday's Pre-Market Session
- NewsAvi Kapoor
S&P Moves Lower; Domino's Pizza Posts Mixed Q3 Results
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.